Abstract
Background: Drug-coated balloons (DCB) are frequently used to treat femoropopliteal artery disease. However, patency loss occurs in ≥10% of patients within 12 months posttreatment with poor understanding of the underlying mechanisms. Objectives: The authors sought to investigate the determinants of DCB failure in femoropopliteal disease. Methods: Data from randomized clinical trials (IN.PACT SFA, MDT-2113 SFA Japan) and 2 prespecified imaging cohorts of the IN.PACT Global Clinical Study were included. Influential procedural characteristics were evaluated by an independent angiographic core laboratory. The primary endpoint was DCB failure (patency loss during follow-up). Additional endpoints were binary restenosis and clinically driven target lesion revascularization. Multivariable analyses evaluated the clinical, anatomical, and procedural predictors of DCB failure. Results: Included were 557 participants with single lesions and 12-month core laboratory–adjudicated duplex ultrasonography. Key clinical characteristics were as follows: mean age 68.8 years, 67.5% male, 87.6% with hypertension, 76.9% with hyperlipidemia, 40.5% with diabetes mellitus, 90.5% in Rutherford Classification Category (RCC) 2 to 3, and 9.5% in RCC 4 to 5. Average length and reference vessel diameter (RVD) were 16.37 cm and 4.66 mm, respectively; 49.7% of lesions were totally occluded. In multivariable analysis, only residual stenosis >30% was associated with patency loss, whereas residual stenosis >30% and smaller preprocedure RVD were associated with increased binary restenosis risk. RCC >3 and residual stenosis >30% were associated with increased 12-month clinically driven target lesion revascularization risk. Conclusions: Patency loss after DCB treatment was influenced by procedural and clinical factors. Residual stenosis >30%, smaller preprocedure RVD, and higher RCC may be considered predictors of increased risk of DCB failure and its components in femoropopliteal artery disease. (Randomized Trial of IN.PACT Admiral® Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease [INPACT SFA I]; NCT01175850; IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Artery [SFA] and Proximal Popliteal Artery [PPA] [INPACT SFA II]; NCT01566461; MDT-2113 Drug-Eluting Balloon vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery [MDT-2113 SFA]; NCT01947478; IN.PACT
Original language | English (US) |
---|---|
Pages (from-to) | 1241-1250 |
Number of pages | 10 |
Journal | Journal of the American College of Cardiology |
Volume | 80 |
Issue number | 13 |
DOIs | |
State | Published - Sep 27 2022 |
Externally published | Yes |
Keywords
- drug-coated balloon
- drug-coated balloon failure
- femoropopliteal artery
- peripheral artery disease
- restenosis
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention'. Together they form a unique fingerprint.
View full fingerprint
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Krishnan, P., Farhan, S., Schneider, P., Kamran, H., Iida, O., Brodmann, M., Micari, A., Sachar, R., Urasawa, K., Scheinert, D., Ando, K., Tarricone, A., Doros, G., Tepe, G., Yokoi, H., Laird, J., & Zeller, T. (2022). Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention. Journal of the American College of Cardiology, 80(13), 1241-1250. https://doi.org/10.1016/j.jacc.2022.06.043
Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention. / Krishnan, Prakash; Farhan, Serdar; Schneider, Peter et al.
In: Journal of the American College of Cardiology, Vol. 80, No. 13, 27.09.2022, p. 1241-1250.
Research output: Contribution to journal › Article › peer-review
Krishnan, P, Farhan, S, Schneider, P, Kamran, H, Iida, O, Brodmann, M, Micari, A, Sachar, R, Urasawa, K, Scheinert, D, Ando, K, Tarricone, A, Doros, G, Tepe, G, Yokoi, H, Laird, J & Zeller, T 2022, 'Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention', Journal of the American College of Cardiology, vol. 80, no. 13, pp. 1241-1250. https://doi.org/10.1016/j.jacc.2022.06.043
Krishnan P, Farhan S, Schneider P, Kamran H, Iida O, Brodmann M et al. Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention. Journal of the American College of Cardiology. 2022 Sep 27;80(13):1241-1250. doi: 10.1016/j.jacc.2022.06.043
Krishnan, Prakash ; Farhan, Serdar ; Schneider, Peter et al. / Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention. In: Journal of the American College of Cardiology. 2022 ; Vol. 80, No. 13. pp. 1241-1250.
@article{9b0daaa1d4d64e5a8dfc5a70633ad7bf,
title = "Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention",
abstract = "Background: Drug-coated balloons (DCB) are frequently used to treat femoropopliteal artery disease. However, patency loss occurs in ≥10% of patients within 12 months posttreatment with poor understanding of the underlying mechanisms. Objectives: The authors sought to investigate the determinants of DCB failure in femoropopliteal disease. Methods: Data from randomized clinical trials (IN.PACT SFA, MDT-2113 SFA Japan) and 2 prespecified imaging cohorts of the IN.PACT Global Clinical Study were included. Influential procedural characteristics were evaluated by an independent angiographic core laboratory. The primary endpoint was DCB failure (patency loss during follow-up). Additional endpoints were binary restenosis and clinically driven target lesion revascularization. Multivariable analyses evaluated the clinical, anatomical, and procedural predictors of DCB failure. Results: Included were 557 participants with single lesions and 12-month core laboratory–adjudicated duplex ultrasonography. Key clinical characteristics were as follows: mean age 68.8 years, 67.5% male, 87.6% with hypertension, 76.9% with hyperlipidemia, 40.5% with diabetes mellitus, 90.5% in Rutherford Classification Category (RCC) 2 to 3, and 9.5% in RCC 4 to 5. Average length and reference vessel diameter (RVD) were 16.37 cm and 4.66 mm, respectively; 49.7% of lesions were totally occluded. In multivariable analysis, only residual stenosis >30% was associated with patency loss, whereas residual stenosis >30% and smaller preprocedure RVD were associated with increased binary restenosis risk. RCC >3 and residual stenosis >30% were associated with increased 12-month clinically driven target lesion revascularization risk. Conclusions: Patency loss after DCB treatment was influenced by procedural and clinical factors. Residual stenosis >30%, smaller preprocedure RVD, and higher RCC may be considered predictors of increased risk of DCB failure and its components in femoropopliteal artery disease. (Randomized Trial of IN.PACT Admiral{\textregistered} Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease [INPACT SFA I]; NCT01175850; IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Artery [SFA] and Proximal Popliteal Artery [PPA] [INPACT SFA II]; NCT01566461; MDT-2113 Drug-Eluting Balloon vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery [MDT-2113 SFA]; NCT01947478; IN.PACT",
keywords = "drug-coated balloon, drug-coated balloon failure, femoropopliteal artery, peripheral artery disease, restenosis",
author = "Prakash Krishnan and Serdar Farhan and Peter Schneider and Haroon Kamran and Osamu Iida and Marianne Brodmann and Antonio Micari and Ravish Sachar and Kasuki Urasawa and Dierk Scheinert and Kenji Ando and Arthur Tarricone and Gheorghe Doros and Gunnar Tepe and Hiroyoshi Yokoi and John Laird and Thomas Zeller",
note = "Publisher Copyright: {\textcopyright} 2022 The Authors",
year = "2022",
month = sep,
day = "27",
doi = "10.1016/j.jacc.2022.06.043",
language = "English (US)",
volume = "80",
pages = "1241--1250",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "13",
}
TY - JOUR
T1 - Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention
AU - Krishnan, Prakash
AU - Farhan, Serdar
AU - Schneider, Peter
AU - Kamran, Haroon
AU - Iida, Osamu
AU - Brodmann, Marianne
AU - Micari, Antonio
AU - Sachar, Ravish
AU - Urasawa, Kasuki
AU - Scheinert, Dierk
AU - Ando, Kenji
AU - Tarricone, Arthur
AU - Doros, Gheorghe
AU - Tepe, Gunnar
AU - Yokoi, Hiroyoshi
AU - Laird, John
AU - Zeller, Thomas
N1 - Publisher Copyright:© 2022 The Authors
PY - 2022/9/27
Y1 - 2022/9/27
N2 - Background: Drug-coated balloons (DCB) are frequently used to treat femoropopliteal artery disease. However, patency loss occurs in ≥10% of patients within 12 months posttreatment with poor understanding of the underlying mechanisms. Objectives: The authors sought to investigate the determinants of DCB failure in femoropopliteal disease. Methods: Data from randomized clinical trials (IN.PACT SFA, MDT-2113 SFA Japan) and 2 prespecified imaging cohorts of the IN.PACT Global Clinical Study were included. Influential procedural characteristics were evaluated by an independent angiographic core laboratory. The primary endpoint was DCB failure (patency loss during follow-up). Additional endpoints were binary restenosis and clinically driven target lesion revascularization. Multivariable analyses evaluated the clinical, anatomical, and procedural predictors of DCB failure. Results: Included were 557 participants with single lesions and 12-month core laboratory–adjudicated duplex ultrasonography. Key clinical characteristics were as follows: mean age 68.8 years, 67.5% male, 87.6% with hypertension, 76.9% with hyperlipidemia, 40.5% with diabetes mellitus, 90.5% in Rutherford Classification Category (RCC) 2 to 3, and 9.5% in RCC 4 to 5. Average length and reference vessel diameter (RVD) were 16.37 cm and 4.66 mm, respectively; 49.7% of lesions were totally occluded. In multivariable analysis, only residual stenosis >30% was associated with patency loss, whereas residual stenosis >30% and smaller preprocedure RVD were associated with increased binary restenosis risk. RCC >3 and residual stenosis >30% were associated with increased 12-month clinically driven target lesion revascularization risk. Conclusions: Patency loss after DCB treatment was influenced by procedural and clinical factors. Residual stenosis >30%, smaller preprocedure RVD, and higher RCC may be considered predictors of increased risk of DCB failure and its components in femoropopliteal artery disease. (Randomized Trial of IN.PACT Admiral® Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease [INPACT SFA I]; NCT01175850; IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Artery [SFA] and Proximal Popliteal Artery [PPA] [INPACT SFA II]; NCT01566461; MDT-2113 Drug-Eluting Balloon vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery [MDT-2113 SFA]; NCT01947478; IN.PACT
AB - Background: Drug-coated balloons (DCB) are frequently used to treat femoropopliteal artery disease. However, patency loss occurs in ≥10% of patients within 12 months posttreatment with poor understanding of the underlying mechanisms. Objectives: The authors sought to investigate the determinants of DCB failure in femoropopliteal disease. Methods: Data from randomized clinical trials (IN.PACT SFA, MDT-2113 SFA Japan) and 2 prespecified imaging cohorts of the IN.PACT Global Clinical Study were included. Influential procedural characteristics were evaluated by an independent angiographic core laboratory. The primary endpoint was DCB failure (patency loss during follow-up). Additional endpoints were binary restenosis and clinically driven target lesion revascularization. Multivariable analyses evaluated the clinical, anatomical, and procedural predictors of DCB failure. Results: Included were 557 participants with single lesions and 12-month core laboratory–adjudicated duplex ultrasonography. Key clinical characteristics were as follows: mean age 68.8 years, 67.5% male, 87.6% with hypertension, 76.9% with hyperlipidemia, 40.5% with diabetes mellitus, 90.5% in Rutherford Classification Category (RCC) 2 to 3, and 9.5% in RCC 4 to 5. Average length and reference vessel diameter (RVD) were 16.37 cm and 4.66 mm, respectively; 49.7% of lesions were totally occluded. In multivariable analysis, only residual stenosis >30% was associated with patency loss, whereas residual stenosis >30% and smaller preprocedure RVD were associated with increased binary restenosis risk. RCC >3 and residual stenosis >30% were associated with increased 12-month clinically driven target lesion revascularization risk. Conclusions: Patency loss after DCB treatment was influenced by procedural and clinical factors. Residual stenosis >30%, smaller preprocedure RVD, and higher RCC may be considered predictors of increased risk of DCB failure and its components in femoropopliteal artery disease. (Randomized Trial of IN.PACT Admiral® Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease [INPACT SFA I]; NCT01175850; IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Artery [SFA] and Proximal Popliteal Artery [PPA] [INPACT SFA II]; NCT01566461; MDT-2113 Drug-Eluting Balloon vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery [MDT-2113 SFA]; NCT01947478; IN.PACT
KW - drug-coated balloon
KW - drug-coated balloon failure
KW - femoropopliteal artery
KW - peripheral artery disease
KW - restenosis
UR - http://www.scopus.com/inward/record.url?scp=85137565980&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137565980&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2022.06.043
DO - 10.1016/j.jacc.2022.06.043
M3 - Article
C2 - 36137674
AN - SCOPUS:85137565980
SN - 0735-1097
VL - 80
SP - 1241
EP - 1250
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 13
ER -